Nuvalent, Inc. Class A Common Stock earnings per share and revenue
On 30 de out. de 2025, NUVL reported earnings of -1.70 USD per share (EPS) for Q3 25, missing the estimate of -1.40 USD, resulting in a -21.38% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -4.66% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 19 analistas forecast an EPS of -1.50 USD, with revenue projected to reach -- USD, implying an diminuir of -11.76% EPS, and aumentar of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Holdings Inc. Common Stock
Report Date
22 de dez. de 2025 Para Q4 25
Estimativa
-$0.57
Real
-$0.73
Surpresa
-25.95%
Outlook Therapeutics, Inc. Common Stock
Report Date
19 de dez. de 2025 Para Q4 25
Estimativa
-$0.25
Real
-$0.19
Surpresa
+26.47%
Citius Oncology, Inc. Common Stock
Report Date
23 de dez. de 2025 Para Q4 25
Estimativa
-$0.12
Real
-$0.06
Surpresa
+50.98%
FAQ
What were Nuvalent, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Nuvalent, Inc. Class A Common Stock reported EPS of -$1.70, missing estimates by -21.38%, and revenue of $0.00, 0% as expectations.
How did the market react to Nuvalent, Inc. Class A Common Stock's Q3 2025 earnings?
The stock price moved down -4.66%, changed from $102.97 before the earnings release to $98.17 the day after.
When is Nuvalent, Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for 25 de fev. de 2026.
What are the forecasts for Nuvalent, Inc. Class A Common Stock's next earnings report?
Based on 19
analistas, Nuvalent, Inc. Class A Common Stock is expected to report EPS of -$1.50 and revenue of -- for Q4 2025.